◆ FUNDING DATA
- Location
- Boston, United States
- Priority score
- 50/100
- Confidence
- 65/100
Oxeia Biopharmaceuticals.
Oxeia Biopharmaceuticals is developing OXE103, a synthetic human ghrelin, to treat mild traumatic brain injury (concussion) by addressing neuro-metabolic dysfunction and axonal injury.